Trial Profile

Brightline-3: A Phase III, Randomized, Open-label, Multi-center Trial of Brigimadlin + Ezabenlimab Compared to Gemcitabine + Docetaxel for Second-line Treatment of Patients With Advanced TP53 Wild-type Soft Tissue Sarcoma Subtypes

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 23 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brigimadlin (Primary) ; Ezabenlimab (Primary) ; Docetaxel; Gemcitabine
Indications Malignant fibrous histiocytoma; Soft tissue sarcoma
Focus Therapeutic Use
Acronyms Brightline-3
Sponsors Boehringer Ingelheim

17 Jul 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
13 May 2024 Planned initiation date changed from 4 Jun 2024 to 27 Jun 2024.
22 Apr 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com